

Raptor Pharmaceutical Corp  
Form 8-K  
November 12, 2010

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2010

RAPTOR PHARMACEUTICAL CORP.

(Exact name of registrant as specified in its charter)

|   |                          |                                      |
|---|--------------------------|--------------------------------------|
| Delaware  | 000-25571                | 86-0883978                           |
| (State or other jurisdiction of<br>incorporation) | (Commission File Number) | (IRS Employer Identification<br>No.) |

9 Commercial Blvd., Suite 200, Novato, California 94949  
(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (415) 382-8111

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 8.01 Other Events.

On November 8, 2010, Raptor Pharmaceutical Corp., a Delaware corporation (the “Company”), issued a press release announcing that (i) the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington’s Disease, (ii) the Company was granted an aggregate of \$1 million of Qualifying Therapeutic Discovery Project grants from the U.S. Government for five of the Company’s research programs, and (iii) a new patent will be issued to the Company adding to its NeuroTrans™ portfolio.

The Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit<br>No. | Exhibit Description   | Filed        | Form | Incorporated by Reference |         |             | Filed By |
|----------------|---|--------------|------|---------------------------|---------|-------------|----------|
|                |   | Here<br>with |      | File No.                  | Exhibit | Filing Date |          |
| 99.1           | Press release issued<br>by the Company dated<br>as of November 8,<br>2010 | X            |      |                           |         |             |          |

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

Date: November 12, 2010

By: /s/ Kim R. Tsuchimoto  
Name: Kim R. Tsuchimoto  
Title: Chief Financial Officer, Treasurer and  
Secretary

Exhibit Index

| Exhibit<br>No. | Exhibit Description   | Filed<br>Here<br>with | Form | File No. | Incorporated by Reference |             | Filed By |
|----------------|---|-----------------------|------|----------|---------------------------|-------------|----------|
|                |   |                       |      |          | Exhibit                   | Filing Date |          |
| 99.1           | Press release issued<br>by the Company dated<br>as of November 8,<br>2010 | X                     |      |          |                           |             |          |